The nucleophosmin (NPM1) gene encodes for a multifunctional chaperone protein that is
localized in the nucleolus but continuously shuttles between the nucleus and cytoplasm …

The mechanistic target of rapamycin (mTOR) is evolutionarily conserved from yeast to
humans and is one of the most fundamental pathways of living organisms. Since its …

NPM 1-mutated acute myeloid leukemia (AML) shows unique features. However, the
characteristics of “therapy-related” NPM1-mutated AML (t-NPM1 AML) are poorly …

Mutations in NPM1, also known as nucleophosmin-1, B23, NO38, or numatrin, are seen in
approximately one-third of patients with acute myeloid leukaemia (AML). A plethora of …

Hematopoietic stem cell (HSC) mutations can result in clonal hematopoiesis (CH) with
heterogeneous clinical outcomes. Here, we investigate how the cell state preceding Tet2 …

Somatic mutations in the nucleophosmin (NPM1) gene occur in approximately 30% of de
novo acute myeloid leukemias (AMLs) and are relatively enriched in normal karyotype …

Hematopoiesis is an essential process for organismal development and homeostasis.
Epigenetic regulation of gene expression is critical for stem cell self-renewal and …

Hematopoietic stem cells (HSCs) ensure the coordinated and balanced production of all
hematopoietic cell types throughout life. Aging is associated with a gradual decline of the …

The 2022 WHO revision and the ICC classification have recently modified the diagnostic
criteria for chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia …

Acute myeloid leukemia (AML) patients with DNA methyltransferase 3A (DNMT3A) mutation
display poor prognosis, and targeted therapy is not available currently. Our previous study …